Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?

Breast Cancer Res Treat. 2024 Jan;203(1):183-184. doi: 10.1007/s10549-023-07154-0. Epub 2023 Oct 7.

Authors

Rossana Roncato¹, Fabio Puglisi^{1

2}, Lorenzo Gerratana³

Affiliations

¹ Department of Medicine, University of Udine, Udine, Italy.
² Department of Medical Oncology, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy.
³ Department of Medical Oncology, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy. gerratana.lorenzo@spes.uniud.it.

PMID: 37804389
DOI: 10.1007/s10549-023-07154-0

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Body Mass Index
Breast Neoplasms* / chemically induced
Female
Humans
Piperazines / adverse effects
Pyridines / adverse effects
Receptor, ErbB-2

Substances

palbociclib
Piperazines
Pyridines
Receptor, ErbB-2